Clinical Trials

Welcome to South East Retina Center –Clinical Trial Research Division!

Southeast Retina Center Clinical Trial Division has brought cutting edge therapies to our community and patients. Drs. Marcus and Lalane have been clinical research investigators for many of the clinical trials investigating new state-of-the-art therapies for retinal diseases. Several of these therapies, such as anti-vascular endothelial growth factor (anti-VEGF) injections were evaluated in our office as part of clinical trials. Patients participating in clinical trials at Southeast Retina Center had the opportunity to receive therapies prior to their availability. Many treatments such as anti-VEGF injections were subsequently FDA approved and are now are standard treatment for many blinding retinal disorders such as wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. Our clinical trial research division continues to study and evaluate new preventative and therapeutic treatments as we participate in numerous clinical trials and studies ranging from Phase I through Phase IV.


Our Physicians  are  national leaders in clinical research as they continue to offer our patients cutting edge therapies in trials sponsored by the National Eye Institute and leading pharmaceutical companies. Our practice has participated in the internationally recognized, National Eye Institute-sponsored Diabetic Retinopathy Clinical Research (DRCR) Network which is a leading entity for vital research for our diabetic patients. Dr. Marcus has served in several leadership roles for the Network including the DRCR executive committee, protocol chairman, DRCR writing committees and protocol development committees. Dr. Marcus is national protocol chairman for the DRCR Protocol AA evaluating wide field imaging of the retina in diabetic retinopathy.  Wide field imaging may provide a more comfortable way for patients undergoing photography of their retinas.  Dr. Lalane has published a comprehensive review in a medical journal discussing this new technology of wide field imaging.   Dr. Marcus has served and continues to serve in a leadership position for several pharmaceutical study steering committees including evaluation of a surgically implanted device which slowly releases anti-VEGF medicine in the eye.  This device may potentially limit the number of eye injections a patient needs to have.  Dr. Marcus has helped developing and revising the surgical technique for device placement and in study protocol development and oversight.  Our physicians also have devised unique approaches to the surgical removal of blood in diabetic eyes and have coined the term “endolaserless” surgical vitrectomy.  Drs. Marcus and Lalane continue to study this technique within our clinical research unit as part of their clinical trial, known as the LASER LESS Trial.  With this technique they are studying whether omitting laser during blood removal in a diabetic patient can lead to better vision while saving patients from the side effects of laser. 

Our dedicated Certified Research staff brings extensive experience in quality data capture, visual function examinations, ophthalmic photography, OCT  and OCT angiography, wide field retinal imaging, retinal visual field and  microperimetry testing , retinal electrophysiology and ultrasonography.  Our staff has cross-certification for various studies, strict protocol adherence and good clinical practice guidelines. Our site had been recognized as “Clinical Research Site of the Month” by the DRCR network.

Our imaging section performs anterior and posterior segment photography/fluorescein and indocyanine green angiography, posterior segment OCT (Cirrus, Heidelberg Spectralis ), HRT III, Corneal Topography (, microperimetry, and diagnostic and biometric ultrasonography .The visual field section employs Humphrey perimeters and on-site electrophysiology testing. Biologic specimens are collected, centrifuged, stored (-20F and -86F freezers), packaged under CLIA accreditation and shipped by EHSO certified personnel.
This extensive experience in well-designed, controlled clinical trials has made us one of today’s nationally recognized leaders in retina based clinical research. Our doctors take pride in offering the most promising vision-saving treatment to our patients.

Why consider us for as your next Research Site?

Our Facility boasts:

  • 1000 sq ft. Dedicated Clinical research wing
  • State-of-the-art imaging /diagnostic equipment
  • Dedicated, visual acuity testing room
  • Designated monitoring rooms with high speed internet and phone access
  • 4 dedicated experienced Certified clinical research coordinators
  • Dedicated RNs able to participate in Infusion studies
  • CPR and ACLS certified RNs
  • Certified Ophthalmic Technicians and Photographers
  • Trained personnel for handling/preparing for transportation of dangerous goods
  • Practice of Good Clinical Practice guidelines
  • Customized standard operating procedures
  • Excellent subject retention
  • Direct oversight by PI/Research Director

 

Trials and studies Current clinical trials at Southeast Retina center

Sponsor – Protocol

INDICATION

ALIMERA PALADIN

Diabetic Macular Edema

ALLERGAN SEQUOIA

Choroidal Neovascularization

 

ALLERGAN ACACIA

Diabetic Macular Edema

ALLEGRO DME 202

STAGE II

Diabetic Macular Edema

ALLEGRO DME

STAGE III

Diabetic Macular Edema

APELLIS FILLY

Geographic Atrophy

CLEARSIDE SAPPHIRE

Branch Retinal Vein Occlusion

COHERUS BIOSCIENCES

SUBFOVEAL CNV

DRCR AA

Non Proliferative Diabetic Retinopathy

DRCR AB

Vitreous Hemorrhage

DRCR S

Proliferative Diabetic Retinopathy

DRCR U

Diabetic Macular Edema

DRCR V

Diabetic Macular Edema

DRCR W

Non Proliferative Diabetic Retinopathy

GENENTECH LADDER

Choroidal Neovascularization

 

GENENTECH OLEI

Geographic Atrophy

GENENTECH OMASPECT

Geographic Atrophy

GILEAD SCIENCES

 

UVEITIS

LASERLESS

Vitreous Hemorrhage

NOVARTIS PHARMACEUTICALS

Macular Edema secondary to DM, CNV, RVO

OHR PHARMACEUTICALS

Choroidal Neovascularization

 

OPH1003

 

Choroidal Neovascularization

 

OPH1005

 

Choroidal Neovascularization

 

OPH1006

 

Choroidal Neovascularization

 

REGENERON CAPELLA

Choroidal Neovascularization

 

REGENERON ONYX

Choroidal Neovascularization

 

REGENERON PANORAMA

Diabetic Retinopathy

REGENERON RUBY

Diabetic Macular Edema

ROCHE AVENUE

CNV

ROCHE BOULEVARD

Diabetic Macular Edema

ROCHE STAIRWAY

Choroidal Neovascularization

 

ROTATED

Diabetic Macular Edema

SAMSUNG

Choroidal Neovascularization

 

SCORE2

 

Branch Retinal Vein Occlusion

TYROGENEX

Choroidal Neovascularization

 

 

 

 

 

 

 

Past Clinical Trials

Sponsor-protocol

Indication

Alcon Osprey

Exudative Age Related Macular Degeneration

Genentech High Tide Poly

Neovascular Polypoidal Choroidal Vasculopathy

Regeneron Vista

Diabetic Macular Edema

Regeneron View 1 ext

Age Related Macular Degeneration

Regeneron Vibrant

Branch Retinal Vein Occlusion

DRCR Eva Low contrast

n/a

Quark Pharm. Quark

Diabetic Macular Edema

Alimera fame

Diabetic Macular Edema

Genentech Retain

Retinal Vein Occlusion

Alimera Fame Ext

Diabetic Macular Edema

JDRF  Read 3

Diabetic Macular Edema

Pfizer Biotx

Dry Age Related Macular Degeneration

DRCR Protocol I

Diabetic Macular Edema

DRCR Protocol N

Vitreous Hemorrhage

Genentech Mahalo

Geographic Atrophy

Pfizer B181003

Geographic Atrophy

Lpath Nexus

Age Related Macular Degeneration

DRCR Protocol R

Non Central Diabetic Macular Edema

 Acucela Seatle

Geographic Atrophy associated with Dry Age Related Macular Degeneration

Allergan Palm

Diabetic Macular Edema

Genentech Chroma

Geographic Atrophy secondary to Age Related Macular Degeneration

Genentech Eclipse

Subfoveal Neovascular Age Related Macular Degeneration

Pfizer B1261009

Diabetic Macular Edema

Regeneron Review

Neovascular Age Related Macular Degeneration

Regeneron Rival

Neovascular Polypoidal Choroidal Vasculopathy

Regeneron Range

Wet Age Related Macular Degeneration

Regeneron Handle

Wet Ocular Histoplasmosis

 

If you are a Sponsor /CRO please contact the Clinical Research Manager- Christina Rex at 706-650-0061 ,  if you are interested in working with us as a site.

If you are a patient interested in determining your eligibility for a trial, please contact our Clinical Research Coordinators - Siobhan Ortiz CCRC, Department Lead at

706-650- 0061